Protocol Ledger

NCT03434353 · Phase II · TERMINATED

Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)

Interventional Phase II clinical trial protocol NCT03434353 sponsored by Gilead Sciences in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-02-28 Enrollment: 123 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03434353
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)123 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03434353
Protocol FieldVerified Registry Value
NCT IdentifierNCT03434353
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment123 participants (ACTUAL)
Registered Start Date2018-02-28
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03434353
Hospital Research SiteLocationSite Profile
Kyungpook National University HospitalDaegu, South KoreaOpen Hospital Dossier ->
Severance Hospital, Yonsei University Health SystemSeoul, South KoreaOpen Hospital Dossier ->
Asan Medical CenterSeoul, South KoreaOpen Hospital Dossier ->
Korea University Guro HospitalSeoul, South KoreaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI